Scotiabank analyst Louise Chen lowered the firm’s price target on Aclaris Therapeutics (ACRS) to $9 from $15 and keeps an Outperform rating on the shares. The firm is lowering its price target on the stock due to lower sales for bosakitug, the analyst tells investors. The firm, however, continues to believe pipeline advancements and commercialization, as well as potential partnerships, will drive upwards earnings revisions.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRS:
- Aclaris Therapeutics Reports Q1 2025 Financial Results
- Aclaris Therapeutics reports Q1 EPS (12c), consensus (12c)
- Aclaris Therapeutics appoints Hall as Chief Medical Officer
- Aclaris Therapeutics: Promising Pipeline and Strategic Developments Justify Buy Rating
- Aclaris Therapeutics’ IND for ATI-052 candidate granted FDA clearance
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue